Search

everythinglearnresearchcommunity

for

Search:↓

Transgender individuals may face specific skin issues during gender-affirming treatments, needing personalized care.

The safety and effectiveness of gender-affirming treatments for children are uncertain, with potential long-term risks like infertility.

The document concludes that gender-affirming treatments are essential for transgender individuals and outlines safe hormone therapy practices.

The guidelines recommend informed consent for gender-affirming treatments and stress the importance of personalized, culturally sensitive care for transgender individuals.

The guideline emphasizes a multidisciplinary approach and informed consent for gender-affirming hormone treatment, with regular follow-ups and individualized care.

Gender-affirming care for youth remained essential during the COVID-19 pandemic, with telemedicine playing a key role.

The document concludes that respectful, gender-affirming healthcare improves mental health and encourages continued medical care for transgender and non-binary individuals.

The guideline provides healthcare professionals in South Africa with instructions for comprehensive, multidisciplinary gender-affirming care, including HIV prevention and treatment for transgender and gender diverse individuals.

Dermatologists should address discrimination and consider ethnic and gender differences in treatments.

AGA treatments like minoxidil and LLLLT are safe and effective for gender minority patients.

The conclusion is that recognizing the difference between gender identity and biological sex is crucial in dermatology to improve patient care and research accuracy.

Transgender individuals face unique skin issues, often due to hormone therapy, requiring specialized and stigma-free dermatologic care.

Gender-affirming hormone treatments need better patient-focused outcome measurements and standardized data collection.

Early medical support for transgender youth is important for their health, with low regret for gender-affirming hormone use and a need for knowledgeable care providers.

Gender-affirming dermatology treatments generally improve mental well-being for transgender individuals, but more research is needed.

The document advises health care providers on how to support transgender and gender-diverse youth with appropriate care and referrals.

Testosterone treatment may change estrogen receptor methylation in AFAB individuals.

Hormonal treatment in transgender women reduces semen quality, but stopping treatment may improve it.

The statement offers guidance for hormone therapy and surgery to help gender-incongruent adults affirm a male identity.

Athletic trainers should understand and support the medical needs of transgender and gender-diverse patients.

Australia needs better dermatological guidelines for gender-diverse patients.

Understanding sex and gender differences can improve personalized dermatology care.

Most transgender adolescents continued hormone treatment, with few stopping due to reasons other than returning to their birth gender.

Facial hair is crucial for gender affirmation, but many face financial barriers to achieving desired results.

Gender-affirming hormone therapy changes hair growth in transgender people, with feminizing therapy reducing hair and masculinizing therapy increasing it, but sometimes additional treatment is needed.

Future hormone therapy trials should match the diverse needs and priorities of the gender-diverse community.

Hormone therapy for transgender females increases the risk of blood clots and requires careful dosing, monitoring, and lifelong management.

Younger transgender women have surgery earlier, are mostly attracted to men, and show more preoperative depression that improves after surgery compared to older transgender women.

BMI is not a significant predictor of complications after gender-affirming penile inversion vaginoplasty.

PrEP for HIV is less effective in transgender women mainly due to low adherence to the treatment.